Drug Profile
AMY 109
Alternative Names: AMY-109Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometriosis
- No development reported Solid tumours
Most Recent Events
- 31 Jan 2024 Phase-II clinical trials in Endometriosis in World (SC) (Chugai pharmaceutical pipeline, February 2024)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (Parenteral, Injection)
- 24 Oct 2023 Phase-I clinical trials in Endometriosis in World (SC)